Boston Operating Income from 2010 to 2025

BSX Stock

USD 101.56 0.84 0.83%

Boston Scientific Operating Income yearly trend continues to be fairly stable with very little volatility. Operating Income is likely to outpace its year average in 2025. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Boston Scientific Corp generates from its operations. View All Fundamentals

Operating Income

First Reported

1991-03-31

Previous Quarter

733 M

Current Value

675 M

Quarterly Volatility

593.7 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Boston Scientific financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Boston Scientific's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 B, Interest Expense of 198.1 M or Selling General Administrative of 6.3 B, as well as many indicators such as Price To Sales Ratio of 4.7, Dividend Yield of 4.0E-4 or PTB Ratio of 5.9. Boston financial statements analysis is a perfect complement when working with Boston Scientific Valuation or Volatility modules.

Check out the analysis of Boston Scientific Correlation against competitors.

Latest Boston Scientific's Operating Income Growth Pattern

Below is the plot of the Operating Income of Boston Scientific Corp over the last few years. Operating Income is the amount of profit realized from Boston Scientific Corp operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Boston Scientific Corp is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Boston Scientific's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Boston Scientific's overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Boston Operating Income Regression Statistics

	Arithmetic Mean	898,103,125
	Geometric Mean	910,391,491
	Coefficient Of Variation	175.42
	Mean Deviation	1,080,889,844
	Median	1,285,000,000
	Standard Deviation	1,575,450,403
	Sample Variance	2482044T
	Range	6.6B
	R-Value	0.74
	Mean Square Error	1201482.2T
	R-Squared	0.55
	Significance	0
	Slope	245,008,456
	Total Sum of Squares	37230659.6T

Boston Operating Income History

	2025	2.7 B
	2024	2.6 B
	2023	2.3 B
	2022	1.6 B
	2021	2 B
	2020	1 B
	2019	1.5 B

Other Fundumenentals of Boston Scientific Corp

Non Operating Income Net Other

Boston Scientific Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Short Term Investments	Common Stock	Long Term Debt	Good Will	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.98	0.95	0.61	0.92	0.95	0.76	0.97	0.4	0.56	0.79	0.63	0.85	0.88	-0.74	0.83	-0.42	0.82	0.71	0.83	-0.6	0.68	0.3	0.65	0.88	0.77	0.76
Total Stockholder Equity	0.98		0.9	0.74	0.92	0.91	0.66	0.95	0.35	0.42	0.77	0.51	0.8	0.88	-0.65	0.81	-0.36	0.88	0.75	0.86	-0.51	0.63	0.27	0.68	0.92	0.8	0.82
Net Debt	0.95	0.9		0.55	0.88	0.95	0.78	0.91	0.54	0.59	0.85	0.62	0.84	0.81	-0.75	0.78	-0.51	0.73	0.71	0.76	-0.67	0.75	0.43	0.52	0.85	0.69	0.69
Retained Earnings	0.61	0.74	0.55		0.68	0.49	0.16	0.57	0.24	-0.22	0.61	-0.14	0.46	0.57	-0.21	0.48	-0.19	0.78	0.78	0.72	-0.16	0.43	0.21	0.59	0.84	0.69	0.76
Accounts Payable	0.92	0.92	0.88	0.68		0.91	0.64	0.91	0.42	0.34	0.84	0.52	0.76	0.83	-0.75	0.81	-0.51	0.84	0.72	0.87	-0.68	0.62	0.31	0.64	0.89	0.75	0.79
Net Receivables	0.95	0.91	0.95	0.49	0.91		0.73	0.91	0.55	0.61	0.77	0.69	0.74	0.82	-0.73	0.79	-0.42	0.75	0.56	0.76	-0.69	0.59	0.45	0.45	0.78	0.58	0.73
Total Liab	0.76	0.66	0.78	0.16	0.64	0.73		0.77	0.24	0.84	0.62	0.86	0.91	0.84	-0.79	0.86	-0.56	0.45	0.61	0.66	-0.61	0.65	0.12	0.51	0.65	0.59	0.38
Total Current Assets	0.97	0.95	0.91	0.57	0.91	0.91	0.77		0.35	0.51	0.81	0.64	0.86	0.84	-0.83	0.81	-0.46	0.83	0.72	0.85	-0.66	0.76	0.24	0.76	0.87	0.83	0.75
Short Term Debt	0.4	0.35	0.54	0.24	0.42	0.55	0.24	0.35		0.24	0.66	0.18	0.1	0.27	-0.25	0.24	-0.2	0.21	0.09	0.29	-0.38	0.34	0.98	-0.07	0.31	0.03	0.39
Intangible Assets	0.56	0.42	0.59	-0.22	0.34	0.61	0.84	0.51	0.24		0.3	0.88	0.62	0.58	-0.52	0.58	-0.3	0.11	0.15	0.25	-0.4	0.32	0.17	0.1	0.26	0.18	0.09
Short Term Investments	0.79	0.77	0.85	0.61	0.84	0.77	0.62	0.81	0.66	0.3		0.38	0.69	0.69	-0.69	0.68	-0.63	0.68	0.68	0.74	-0.67	0.8	0.55	0.59	0.81	0.73	0.62
Common Stock	0.63	0.51	0.62	-0.14	0.52	0.69	0.86	0.64	0.18	0.88	0.38		0.68	0.67	-0.73	0.71	-0.47	0.32	0.27	0.48	-0.64	0.45	0.07	0.29	0.37	0.31	0.31
Long Term Debt	0.85	0.8	0.84	0.46	0.76	0.74	0.91	0.86	0.1	0.62	0.69	0.68		0.87	-0.8	0.87	-0.58	0.66	0.85	0.79	-0.59	0.75	-0.03	0.72	0.84	0.83	0.53
Good Will	0.88	0.88	0.81	0.57	0.83	0.82	0.84	0.84	0.27	0.58	0.69	0.67	0.87		-0.65	0.97	-0.4	0.73	0.76	0.88	-0.49	0.57	0.18	0.61	0.86	0.7	0.7
Treasury Stock	-0.74	-0.65	-0.75	-0.21	-0.75	-0.73	-0.79	-0.83	-0.25	-0.52	-0.69	-0.73	-0.8	-0.65		-0.72	0.58	-0.59	-0.58	-0.69	0.84	-0.72	-0.08	-0.62	-0.66	-0.7	-0.46
Property Plant Equipment	0.83	0.81	0.78	0.48	0.81	0.79	0.86	0.81	0.24	0.58	0.68	0.71	0.87	0.97	-0.72		-0.46	0.72	0.75	0.88	-0.57	0.56	0.14	0.57	0.83	0.68	0.66
Current Deferred Revenue	-0.42	-0.36	-0.51	-0.19	-0.51	-0.42	-0.56	-0.46	-0.2	-0.3	-0.63	-0.47	-0.58	-0.4	0.58	-0.46		-0.3	-0.5	-0.43	0.71	-0.64	-0.1	-0.42	-0.45	-0.5	-0.22
Net Tangible Assets	0.82	0.88	0.73	0.78	0.84	0.75	0.45	0.83	0.21	0.11	0.68	0.32	0.66	0.73	-0.59	0.72	-0.3		0.74	0.86	-0.48	0.62	0.14	0.65	0.87	0.8	0.85
Long Term Debt Total	0.71	0.75	0.71	0.78	0.72	0.56	0.61	0.72	0.09	0.15	0.68	0.27	0.85	0.76	-0.58	0.75	-0.5	0.74		0.86	-0.41	0.72	-0.01	0.76	0.92	0.86	0.67
Capital Surpluse	0.83	0.86	0.76	0.72	0.87	0.76	0.66	0.85	0.29	0.25	0.74	0.48	0.79	0.88	-0.69	0.88	-0.43	0.86	0.86		-0.56	0.67	0.19	0.76	0.93	0.79	0.89
Deferred Long Term Liab	-0.6	-0.51	-0.67	-0.16	-0.68	-0.69	-0.61	-0.66	-0.38	-0.4	-0.67	-0.64	-0.59	-0.49	0.84	-0.57	0.71	-0.48	-0.41	-0.56		-0.63	-0.26	-0.39	-0.51	-0.47	-0.41
Long Term Investments	0.68	0.63	0.75	0.43	0.62	0.59	0.65	0.76	0.34	0.32	0.8	0.45	0.75	0.57	-0.72	0.56	-0.64	0.62	0.72	0.67	-0.63		0.21	0.67	0.69	0.76	0.52
Short Long Term Debt	0.3	0.27	0.43	0.21	0.31	0.45	0.12	0.24	0.98	0.17	0.55	0.07	-0.03	0.18	-0.08	0.14	-0.1	0.14	-0.01	0.19	-0.26	0.21		-0.17	0.22	-0.08	0.34
Cash And Equivalents	0.65	0.68	0.52	0.59	0.64	0.45	0.51	0.76	-0.07	0.1	0.59	0.29	0.72	0.61	-0.62	0.57	-0.42	0.65	0.76	0.76	-0.39	0.67	-0.17		0.75	0.91	0.6
Net Invested Capital	0.88	0.92	0.85	0.84	0.89	0.78	0.65	0.87	0.31	0.26	0.81	0.37	0.84	0.86	-0.66	0.83	-0.45	0.87	0.92	0.93	-0.51	0.69	0.22	0.75		0.87	0.82
Net Working Capital	0.77	0.8	0.69	0.69	0.75	0.58	0.59	0.83	0.03	0.18	0.73	0.31	0.83	0.7	-0.7	0.68	-0.5	0.8	0.86	0.79	-0.47	0.76	-0.08	0.91	0.87		0.59
Capital Stock	0.76	0.82	0.69	0.76	0.79	0.73	0.38	0.75	0.39	0.09	0.62	0.31	0.53	0.7	-0.46	0.66	-0.22	0.85	0.67	0.89	-0.41	0.52	0.34	0.6	0.82	0.59

Click cells to compare fundamentals

About Boston Scientific Financial Statements

Boston Scientific investors use historical fundamental indicators, such as Boston Scientific's Operating Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Boston Scientific. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Operating Income	2.6 B	2.7 B
Non Operating Income Net Other	-43.7 M	-41.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

Additional Tools for Boston Stock Analysis

When running Boston Scientific's price analysis, check to measure Boston Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boston Scientific is operating at the current time. Most of Boston Scientific's value examination focuses on studying past and present price action to predict the probability of Boston Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boston Scientific's price. Additionally, you may evaluate how the addition of Boston Scientific to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Boston Operating Income from 2010 to 2025

Latest Boston Scientific's Operating Income Growth Pattern

Boston Operating Income Regression Statistics

Boston Operating Income History

Other Fundumenentals of Boston Scientific Corp

Boston Scientific Operating Income component correlations

About Boston Scientific Financial Statements

Also Currently Popular

Additional Tools for Boston Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY